The arsenal of TP53 mutants therapies:neoantigens and bispecific antibodies

作     者：Chang Yang Ge Lou Wei-Lin Jin Chang Yang;Ge Lou;Wei-Lin Jin

作者机构：Department of Gynecology OncologyThe Tumor HospitalHarbin Medical UniversityHarbinP.R.China lnstitute of Cancer NeuroscienceMedical Frontier Innovation Research CenterThe First Hospital of Lanzhou UniversityThe First Clinical Medical College of Lanzhou UniversityLanzhouP.R.China 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2021年第6卷第7期

页      面：1935-1936页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：the Harbin Medical University Cancer Hospital(CN)Nn10 Project(Nn10py2017-01) 

主　　题：TP53 antigens 

摘      要：A recent research published in Science by Hsiue et al.1 introduced a CD3-targeting bispecific antibody that can bind to tumor cells by recognizing mutation-associated neoantigens and activate T cell-mediated tumor killing by binding to *** tumor suppressor gene TP53 is the most commonly mutated gene in various cancers.